CD11c mRNA levels were reduced by 1.5 fold in CKD-DTBN treated mice as compared to CKD mice (5-fold and 7.6 fold of C respectively, p < 0.05) (Fig. 5D). Here, ITGAX is linked to chronic kidney disease.